Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 13/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.35 |
| ▸ | ITGAV | P06756 | 1/20 | 0.35 |
| ▸ | FPR1 | P21462 | 2/20 | 0.35 |
| ▸ | FPR2 | P25090 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19544833 | 0.79 | CHRM3 (0.38) | PIN1CHRM3FPR1FPR2 | |
| SCHEMBL19544843 | 0.73 | CTSC (0.40) | CHRM3FPR1FPR2 | |
| SCHEMBL19544579 | 0.73 | CTSC (0.40) | CHRM3FPR1FPR2 | |
| SCHEMBL22582613 | 0.73 | CTSC (0.40) | CHRM3FPR1FPR2 | |
| SCHEMBL19521217 | 0.69 | MMP9 (0.47) | PIN1FPR1FPR2 | |
| SCHEMBL19521215 | 0.69 | MMP9 (0.47) | PIN1FPR1FPR2 | |
| SCHEMBL19544842 | 0.68 | SAE1 (0.50) | CHRM3FPR1FPR2 | |
| SCHEMBL19521201 | 0.65 | CTSC (0.42) | PIN1CHRM3FPR1FPR2 | |
| SCHEMBL19521205 | 0.65 | CTSC (0.42) | PIN1CHRM3FPR1FPR2 | |
| SCHEMBL19544841 | 0.64 | CTSC (0.69) | FPR1FPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200339562-A1 | COVALENT BTK INHIBITORS AND USES THEREOF | MIDCAP FINANCIAL TRUST | 2020-10-29 | — | — | US | disclosed |
| WO-2017190048-A1 | COVALENT BTK INHIBITORS AND USES THEREOF | X-CHEM, INC. (US) | 2017-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200339562-A1 | COVALENT BTK INHIBITORS AND USES THEREOF | BTK, SYK, LYN | PIN1 1079/4885CHRM3 3910/4885ITGB1 1615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.